Important Update for True Blue Savings Cardholders

true blue savings

Do you save money on your Mitigare® (Colchicine) 0.6 mg Capsules or Authorized Generic Colchicine Capsules with a True Blue Savings card? If so, we have important news for you:

 

Your True Blue Savings card will expire at the end of this year—12/31/19.

 

As long as you are still eligible for the program, it’s easy to get a new card and continue to save on Mitigare® or Generic Colchicine Capsules.* Here is more information about this important update for True Blue Savings cardholders and what you need to do to continue to save.

 

 

Download your new card

If you have a True Blue Savings card, it probably looks like this:

Existing True Blue Savings card—expires 12/31/19

 

Between now and the end of 2019, be sure to visit Mitigare.com to download and activate your new True Blue Savings card. Your new card will look like this:

New True Blue Savings card—available now at Mitigare.com

 

When you get your new card, you will continue to receive Mitigare® or Generic Colchicine Capsules for as little as $0 for the first 30 days and get refills for as low as $5 for as long as you are eligible.* Read the complete Terms and Conditions to learn more about the program and eligibility restrictions.

 

Use your new card

Using your new True Blue Savings Card is simple. Just use it the same way as you used your old card—there’s absolutely no difference.

 

Don’t wait

Although your old True Blue Savings card can help you save money through the end of this year, you’ll want to get your new card as soon as you can. There is no need to wait until the official cutoff date of 12/31/19 because your new True Blue Savings card will be effective as soon as you activate it.

 

Call us if you have questions

If you have questions or would like more information about the True Blue Savings program or your new card, be sure to contact us. We’re happy to help.

 

Sign up today

If you take colchicine to prevent gout flares but do not yet have a True Blue Savings card, consider signing up. If you meet the eligibility requirements, the True Blue Savings card can help you to get Mitigare® or Generic Colchicine Capsules for as little as $0 for the first 30 days and refills for as low as $5.* Read the complete Terms and Conditions to learn more about the program and eligibility restrictions.

 

*For all eligible patients 18 years or older who are legal residents of the United States or Puerto Rico. First 30 days are as little as $0 only for eligible patients. Maximum savings of $65 on the first fill and $50 on refills. Please see complete Terms and Conditions.

 

Important Safety Information

Colchicine 0.6 mg capsules are contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment has resulted in life-threatening or fatal colchicine toxicity. Patients with both renal and hepatic impairment should not be given Mitigare®.

Fatal overdoses have been reported with colchicine in adults and children. Keep Mitigare® out of the reach of children.

Blood dyscrasias such as myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, and aplastic anemia have been reported with colchicine used in therapeutic doses.

Monitor for toxicity and if present consider temporary interruption or discontinuation of colchicine.

Drug interaction with dual P-gp and CYP3A4 inhibitors: Co-administration of colchicine with dual P-gp and CYP3A4 inhibitors has resulted in life-threatening interactions and death.

Neuromuscular toxicity and rhabdomyolysis may occur with chronic treatment with colchicine in therapeutic doses, especially in combination with other drugs known to cause this effect. Patients with impaired renal function and elderly patients (including those with normal renal and hepatic function) are at increased risk. Consider temporary interruption or discontinuation of Mitigare®.

 

Please see the full Prescribing Information and Medication Guide for Mitigare® for complete product details.

 

NOTE: This article was not written by a medical professional and is not intended to substitute for the guidance of a physician. These are not Hikma’s recommendations for gout flare prevention, but rather facts and data collected from various reliable medical sources. For a full list of resources and their attributing links, see below.

 

Mitigare® is a registered trademark of Hikma Pharmaceuticals USA Inc.

Important Safety Information for Mitigare® (colchicine) 0.6 mg capsules

  • Colchicine 0.6 mg capsules are contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment has resulted in life-threatening or fatal colchicine toxicity. Patients with both renal and hepatic impairment should not be given Mitigare®.
  • Fatal overdoses have been reported with colchicine in adults and children. Keep Mitigare® out of the reach of children.
  • Blood dyscrasias such as myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, and aplastic anemia have been reported with colchicine used in therapeutic doses.
  • Monitor for toxicity and if present consider temporary interruption or discontinuation of colchicine.
  • Drug interaction with dual P-gp and CYP3A4 inhibitors: Co-administration of colchicine with dual P-gp and CYP3A4 inhibitors has resulted in life-threatening interactions and death.
  • Neuromuscular toxicity and rhabdomyolysis may occur with chronic treatment with colchicine in therapeutic doses, especially in combination with other drugs known to cause this effect. Patients with impaired renal function and elderly patients (including those with normal renal and hepatic function) are at increased risk. Consider temporary interruption or discontinuation of Mitigare®.
  • The most commonly reported adverse reactions with colchicine are gastrointestinal symptoms, including diarrhea, nausea, vomiting, and abdominal pain.

Indication

Mitigare® is indicated for prophylaxis of gout flares in adults. The safety and effectiveness of Mitigare for acute treatment of gout flares during prophylaxis has not been studied.

Mitigare® is not an analgesic medication and should not be used to treat pain from other causes.

For Full Prescribing Information please CLICK HERE and for Medication Guide CLICK HERE.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Manufactured by: West-Ward Columbus Inc., Columbus, OH 43228

Important Safety Information for Mitigare® (colchicine) 0.6 mg capsules

  • Colchicine 0.6 mg capsules are contraindicated in patients with renal or hepatic impairment who are currently prescribed drugs that inhibit both P-gp and CYP3A4. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment has resulted in life-threatening or fatal colchicine toxicity. Patients with both renal and hepatic impairment should not be given Mitigare®.
  • Fatal overdoses have been reported with colchicine in adults and children. Keep Mitigare® out of the reach of children.